Life After Tongue Cancer, & a Total Glossectomy

Source: UCSF Medical Center Author: Sierra Tzoore   Tongue cancer is uncommon, and it's especially unusual for it to strike a young person who doesn't smoke or drink heavily. Kate Brown was just 32 years old, recently married and beginning a new job, when she learned that a spot on her tongue was stage III tongue cancer. Brown was referred to UCSF Medical Center, where surgeons recommended a drastic treatment that was her best shot at survival: a total glossectomy, or tongue removal, followed by chemotherapy and radiation. Four years later, Brown is cancer-free and, unlike many patients who undergo total glossectomy, able to eat and speak understandably. We asked Brown about her treatment and path to recovery. How did you discover you had tongue cancer? A small sore appeared on my tongue when I had a sore throat. I took antibiotics for the sore throat, but the spot was still there after the sore throat subsided. I then started to have ear pain and the sore got larger. I was prescribed antibiotics again. When my doctor looked in my ear she didn't see any swelling, but the earache became unbearably painful. I'd never been in pain like that. In my heart of hearts, I knew at that point that something was terribly wrong, but I wasn't sure what it was. I decided to see another doctor, who referred me to an ear, nose and throat specialist, Dr. Ivor Emanuel at California Pacific Medical Center. Dr. Emanuel's specialty is allergies but I think [...]

2011-08-22T12:33:47-07:00August, 2011|OCF In The News, Oral Cancer News|
Read More

Dental Care Denied by Medicare Turns into Major Lawsuit

Source: Dr.Bicuspid.com Medicare's refusal to cover extensive dental treatment that is often needed to treat patients with diseases such as oral cancer and Sjögren's syndrome is unreasonable and arbitrary, according to a lawsuit pending in U.S. federal court. The litigation, originally filed in 2008 on behalf of one plaintiff, was recently amended by the Center for Medicare Advocacy (CMA) in the U.S. District Court for the District of Arizona against U.S. Health and Human Services Secretary Kathleen Sebelius on behalf of three Medicare beneficiaries who needed medically related dental care stemming from underlying medical conditions. Medicare policy, which excludes coverage of "routine" dental care, does cover dental services when they are "incident to and an integral part of" eligible medical care. Dental procedures that are covered include extractions in preparation of radiation treatment of neoplastic disease, reconstruction of ridges that are performed simultaneously with the surgical removal of oral tumors, and the wiring of teeth if done in connection with jaw fractures. "We have argued that this is a misinterpretation of the Medicare statute," said CMA attorney Sally Hart, who filed the suit. "We think that beneficiaries who require extensive dental services because of damage from Sjögren's syndrome, as well as cancer radiation treatment and other conditions that destroy the production of saliva, should not fall within the exclusion." CMS does not comment on pending litigation, CMS spokesman Tony Salters told DrBicuspid.com. Why coverage denied Each of the plaintiffs in the CMA lawsuit suffered a serious medical condition, resulting in [...]

2011-08-16T16:04:15-07:00August, 2011|Oral Cancer News|
Read More

New Study for Head and Neck Melanomas

Source: MDNews.com ANN ARBOR, MI — A common technique for determining whether melanoma has spread can be used safely and effectively even in tumors from the head and neck area, according to a new study from the University of Michigan Comprehensive Cancer Center. Sentinel lymph node biopsy involves injecting a special dye to identify the first node where cancer would likely spread. If that node is clean, patients can avoid further debilitating surgery to remove multiple lymph nodes. If that node shows cancer, patients know they need the more extensive surgery or further treatment with radiation, chemotherapy or a clinical trial. Patients with larger melanomas are routinely offered this procedure. But many surgeons believed that the complex anatomy combined with the critical nerves and blood vessels in the head and neck area made sentinel lymph node biopsy unsafe and inaccurate for melanomas in that region. In the current study, which appears online in Cancer, researchers looked at 353 head and neck melanoma patients who had received sentinel lymph node biopsy at U-M over a 10-year period. After reviewing patients’ records, the researchers found that the sentinel lymph node could be identified in all but one patient, and no patients sustained permanent nerve injuries during the procedure. About 20 percent of the patients had at least one sentinel node positive for cancer and were referred for a complete dissection to remove additional lymph nodes. Among the remaining 283 patients with negative sentinel nodes, 12 patients recurred in the region where the [...]

2011-08-09T10:30:24-07:00August, 2011|Oral Cancer News|
Read More

Aerosmith’s Bassist is Treated for Tongue Cancer with Laser Surgery

Source: KSAT.com Aerosmith will be performing in Mexico and South America this fall and one of the band members will be along for the tour thanks to a radical medical procedure. In one Aerosmith song, bassist Tom Hamilton sends a message to his throat and tongue cancer with the lyrics "you've got no business with me." Five years ago, Hamilton underwent chemotherapy and radiation for tongue-base cancer, but it came back and extended into his voice box. That is when he turned to Dr. Steven Zeitels. "This is not your classic way, or even traditional way, to try and remove a cancer from the tongue base," Zeitels said. Radical surgery was now Hamilton's only option. But that could leave his voice and breathing passage permanently damaged. "I was just terrified," Hamilton said. "I really though, 'Oh, I am looking at not being able to talk.'" Zeitels has treated vocal cord cancer with the green-light KTP laser, so Hamilton agreed to be the first person treated that way for tongue base cancer. The laser emits a green light, which is concentrated in the extra blood running through the cancer. "Where there is a lot of cancer, there will be a lot of blood," Zeitels said. "Where there is a lot of blood, there will be a lot of combustion so that you are actually watching the tissues burn completely different" But not everyone is a candidate for this surgery. "The second I had a tiny bit of consciousness, the first thing I did was make [...]

2011-08-09T10:30:12-07:00August, 2011|Oral Cancer News|
Read More

Reirradiation Effective in Post-Radiation Sarcoma

Source: MedScape Today News Reirradiation plus hyperthermia is an effective treatment for radiation-associated sarcoma (RAS) and could even cure some of these rare tumors, a small new study suggests. "The reirradiation plus hyperthermia as we used it appears to be quite successful with a very high response rate and reasonable local control rate," Dr. Geertjan van Tienhoven of the Academic Medical Center in Amsterdam, one of the study's authors, told Reuters Health. RAS develops in areas previously reirradiated with 25 to 80 Gray, usually with a latency period of three years or more, and with a different histology from the original tumor, according to a June 28th online paper in Cancer. Dr. van Tienhoven predicts that "radiation-associated sarcomas are going to be more frequent in the future, because of an increasing prevalence of breast cancer survivors who are at risk, be it a low risk, for RAS." These tumors are usually resected with radical surgery and sometimes adjuvant chemotherapy. To date, according the paper, there haven't been any randomized trials or other prospective studies of reirradiation for RAS. "Many papers and textbooks state that radiation shouldn't be done in these tumors because they are caused by radiation. Indeed it sounds counterintuitive to irradiate again," Dr. van Tienhoven said in an interview. But using hyperthermia with reirradiation allows for a lower radiation dose, he and his coauthors explain. The Academic Medical Center and the Institute Verbeeten have "extensive experience" with this approach, for example in breast cancer recurrence in previously irradiated [...]

2011-08-09T10:29:53-07:00August, 2011|Oral Cancer News|
Read More

Cancer Survivor Gears Up for 25 Mile Bike Ride at the Age of 77

Newark, Ohio — A 77-year-old woman and cancer survivor has biked 25 miles routinely in preparation for this month's Pelotonia bicycle race. Beverly Cote started out biking four miles a day and worked her way up to 25 miles, the distance of Pelotonia, 10TV's Andrea Cambern reported Tuesday. Her inspiration came from someone who made history on a bicycle. "I have been bragging about my grandfather ever since I was a kid," Cote said. Her grandfather, John LaFrance, rode from New York to San Francisco in 22 days and made headlines, Cambern reported. "My grandfather did not have a 10-speed back in 1896," Cote said. "If he could do it, I could do it." He was not the only reason she will ride in the annual bike tour to fight cancer.  Cote is a survivor. Over a year ago, she was diagnosed with stage-four throat and tongue cancer. She endured 35 radiation treatments and seven rounds of chemotherapy. "On my last exam with Dr. Old at the James, he said, 'Are you going to ride in Pelotonia, next year?' I told Dr. Old that if he kept me well, for one year, I will ride in it," Cote said. Pelotonia is scheduled to begin on August 19. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

2011-08-05T12:44:45-07:00August, 2011|Oral Cancer News|
Read More

Taking out a cancer’s co-dependency: novel compound selectively kills cancer cells by blocking response to oxidative stress

Source: www.eurekalert.org Author: public release A cancer cell may seem out of control, growing wildly and breaking all the rules of orderly cell life and death. But amid the seeming chaos there is a balance between a cancer cell's revved-up metabolism and skyrocketing levels of cellular stress. Just as a cancer cell depends on a hyperactive metabolism to fuel its rapid growth, it also depends on anti-oxidative enzymes to quench potentially toxic reactive oxygen species (ROS) generated by such high metabolic demand. Scientists at the Broad Institute and Massachusetts General Hospital (MGH) have discovered a novel compound that blocks this response to oxidative stress selectively in cancer cells but spares normal cells, with an effectiveness that surpassed a chemotherapy drug currently used to treat breast cancer. Their findings, based on experiments in cell culture and in mice, appear online in Nature on July 13. The plant-based compound piperlongumine (PL), derived from the fruit of a pepper plant found in southern India and southeast Asia, appears to kill cancer cells by jamming the machinery that dissipates high oxidative stress and the resulting ROS. Normal cells have low levels of ROS, in tune with their more modest metabolism, so they don't need high levels of the anti-oxidant enzymes that PL stymies once they pass a certain threshold. "Piperlongumine targets something that's not thought to be essential in normal cells," said Stuart L. Schreiber, a senior co-author and director of the Broad's Chemical Biology Program. "Cancer cells have a greater dependence on ROS [...]

2011-07-20T05:21:06-07:00July, 2011|Oral Cancer News|
Read More

Sanford researcher to study new oral cancer therapy

Source: www.mdnews.com Author: public release A new Sanford clinical trial will study the safety and effectiveness of a drug treatment on patients receiving radiation and chemotherapy for head and neck cancer. About three to five percent of all cancers reported in the United States are head and neck cancers. Although the incidence of this type of cancer is relatively low, survival rates are poor — with about a 50 percent of patients surviving over the five-year period following diagnosis, according to John Lee, MD, FACS, Principal Investigator of the trial and a Sanford Clinic Ear, Nose and Throat specialist. Lee’s early research led to the discovery that mice treated with the generic drug dichloroacetate (DCA) responded to cancer therapy 30 percent better. He has received approval from the Food and Drug Administration to begin a clinical trial with patients who are receiving treatment for head and neck cancer. The trial will be open to Sanford patients, and others nationwide. “We are proud of and continue to encourage innovative clinical trials at Sanford that helps us further understand the molecular, cellular and genetic basis of cancer,” said David Pearce, PhD, Vice President, Sanford Research in Sioux Falls. Dr. Lee, who was honored in 2010 by the American Cancer Society for his research, has been studying the link between the Human Papilloma Virus (HPV) and the development of head and neck cancers. His research team has tested the treatment of head and neck tumors in mice finding that factors that enhanced the [...]

2011-07-16T11:48:35-07:00July, 2011|Oral Cancer News|
Read More

Study identifies patients best suited to second round of head-and-neck treatment

Source: http://www.oncologynurseadvisor.com/ Author: Delicia Honen Yard A small group of patients with recurrent or second primary head and neck cancer achieved long-term cure after undergoing concomitant chemotherapy with reirradiation. However, the associated risk of severe toxicity demonstrated that only carefully selected patients should undergo treatment readministration. Joseph Salama, MD, formerly with the University of Chicago (Illinois), and colleagues analyzed data from 166 patients with head and neck cancer who had received a first round of radiation followed by a second round plus chemotherapy because their cancer recurred or because they developed a new tumor. After a median follow-up of 53 months among surviving patients, median overall survival was 10.3 months. The 2-year rates for overall survival, disease-free survival, locoregional control, and freedom from distant metastasis were 24.8%, 19.9%, 50.7%, and 61.4%, respectively. Despite yielding a 2-year cure rate of nearly a quarter of the subjects, the second course of treatment was highly toxic: 33 participants (19.9%) died of treatment-related toxicity, and some lost the ability to speak or swallow. The investigators found that certain patients benefited from the second treatment over others: Those who were cancer-free for a longer period of time, did not have chemotherapy with their first course of radiation, were treated with a higher dose of radiation in their second round, and had surgical resection or debulking prior to the second course of radiation were more likely to be cured at 2 years than those who had none or only some of these features. “This can help doctors determine [...]

2011-07-03T09:12:41-07:00July, 2011|Oral Cancer News|
Read More

Palifermin reduces severe mucositis in head and neck cancer

Source: http://www.medscape.com/ Author: Janis C. Kelly Palifermin (Kepivance), which is currently approved for preventing mucositis associated with total-body irradiation and stem-cell transplantation in hematologic malignancies, also prevents oral mucositis in patients with head and neck cancer undergoing radiation and chemotherapy, according to 2 randomized trials published online June 13 in the Journal of Clinical Oncology. Michael Henke, MD, who led both studies, told Medscape Medical News that "this shows for the first time that radiation-induced mucositis can be ameliorated — and this in a phase 2/3 design!" Dr. Henke is from the Department of Radiation Oncology at University Clinic in Freiburg, Germany. The multicenter studies included researchers from Austria, France, Germany, Hungary, Italy, Poland, Spain, the United Kingdom, and the United States. The first study was a double-blind randomized placebo-controlled trial of 186 patients with stage II to IVB carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Treatment included radiation, 60 or 66 Gy, after complete or incomplete resection, delivered at 2 Gy per fraction and 5 fractions per week. Treatment also included cisplatin 100 mg/m2 on days 1 and 22 (and on day 43 with incomplete resection). Patients were randomized to weekly palifermin 120 μg/kg or placebo from 3 days before and throughout radiochemotherapy. The primary end point was the incidence of severe oral mucositis (World Health Organization [WHO] grades 3 to 4). Palifermin reduced oral mucositis incidence to 51% (41 of 92), compared with 67% (63 of 94) with placebo (P = .027), shortened median mucositis from [...]

2011-07-03T09:08:28-07:00July, 2011|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top